Table 2 Univariate and multivariate analysis for overall survival in ESCA

Gender

(Male vs. Female)

0.345

0.854

1.239

0.165

Age

(≥ 65 vs.<65 )

1.246

0.159

0.874

0.109

KPS scores

(<90 vs.≥90)

1.281

0.111

1.054

0.543

Smoking history

(Yes vs.No)

1.036

0.829

1.272

0.007

Drinking history

(Yes vs.No)

0.768

0.082

0.685

0.044

1.027

0.747

Clinical T Stage

(T1 -T2 vs. T3-T4)

1.687

0.005

1.715

0.033

1.753

0.000

1.853

0.008

Clinical N stage

(N0 vs. N+)

1.507

0.018

1.656

0.019

1.595

0.000

2.581

0.000

Gross tumor volume

(continuous variable)

1.006

0.041

1.004

0.181

1.003

0.035

0.107

0.996

Metastatic lymph node volume

(continuous variable)

1.004

0.676

1.004

0.180

Gross tumor length

1.021

0.770

1.087

0.026

1.075

0.022

(continuous variable)

Combination of chemotherapy

(Yes vs.No)

0.209

0.000

0.213

0.000

0.742

0.000

0.533

0.003

Chemotherapy modality (Single-agent vs.

Doublet-agent)

0.771

0.194

0.917

0.482

Double-agent modality

(taxanes + platinum vs. 5-fu + platinum)

0.982

0.927

0.929

0.519

Single-drug modality

(5-FU vs. Cisplatin)

1.721

0.212

1.058

0.869

Chemotherapy Sequence

0.998

0.994

1.006

0.967

(Concurrent vs. Simultaneously)

Utility of Nimotuzumab

(Yes vs.No)

1.172

0.661

1.043

0.822

Utility of immunotherapy (Yes vs.No)

1.239

0.831

0.856

0.662

Number of chemotherapy cycles

(≤ 4 vs.>4)

1.014

0.834

1.135

0.436

Objective response (OR)

(OR vs. .Non-OR)

1.537

0.019

1.243

0.251

1.264

0.021

1.232

0.237

Radiation coverage

0.867

0.411

0.885

0.190

(ENI vs. IFI)

Radiotherapy modality

0.795

0.189

0.876

0.208

(IMRT vs. 3DCRT)

Radiation dose

(≤ 55 Gy vs.>55 Gy)

0.613

0.029

0.552

0.024

1.041

0.735

1.203

0.458